The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
S&P 500 Earnings for 2025 Q1 — Still...
Money’s Not Leaving the Market — It’s Rotating!
From Oversold to Opportunity: Small Caps on the...
Tariffs and weaker beer demand are weighing on...
Essence Fest leads a summer of events for...
Pullbacks & Reversals: Stocks Setting Up for Big...
S&P 500 Earnings for 2025 Q1 — Still...
Market Signals Align – Is a Bigger Move...
MACD Crossovers: Why Most Traders Get It Wrong
Should You Buy Roblox Stock Now? Key Levels...

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Business

Walgreens to close 1,200 stores over the next three years

by admin October 16, 2024
October 16, 2024
Walgreens to close 1,200 stores over the next three years

Walgreens said Tuesday it plans to close 1,200 stores over the next three years as it seeks to further downsize its footprint amid flagging sales and changing consumer behavior.

The pharmacy chain said 500 of the closings would occur over the next 12 months. It estimates a quarter of its 8,700 stores in the U.S. are unprofitable.

Walgreens announced the closures as part of its fiscal fourth-quarter and full-year earnings, which beat Wall Street’s expectations. In a statement, CEO Tim Wentworth acknowledged the company was in the midst of a ‘turnaround’ that would ‘take time.’

‘We are confident it will yield significant financial and consumer benefits over the long term,” Wentworth said.

In June, Walgreens said it planned to close a “significant” number of its underperforming stores by 2027. Tuesday’s announcement appears to be the company’s first exact estimate of how many locations it will shutter.

Both Walgreens and rival CVS are facing a difficult operating environment, fighting to be profitable as consumers shift their habits.

In 2021, CVS said it would close about 900 stores, or about 10% of its U.S. locations, from 2022 to 2024. Rite Aid recently emerged from bankruptcy and will operate as a privately owned company.

Pharmacy chains have been squeezed in part by changes to the prescription drug market, including lower reimbursements from pharmacy benefit managers (PBMs), the third-party companies that manage prescription drug benefits for health insurance companies.

PBMs have been recently accused of inflating drug costs and are the target of multiple legislative and regulatory reforms and actions.

The end result has been a greater number of ‘pharmacy deserts’ across the U.S.

“The retail pharmacy industry is going through a period of soul-searching, trying to understand the best model to reach the consumer,” Neil Saunders, GlobalData’s retail managing director, told CNBC in August.

This post appeared first on NBC NEWS

previous post
Equities Stay Strong as Technology Returns to Out-Performance
next post
Control of the Senate rests on Tester’s appeal in a changing Montana

Related Posts

Amazon taps Whole Foods CEO to oversee grocery...

January 29, 2025

How investors can prepare for lower interest rates:...

August 25, 2024

In wake of L.A. wildfires, a diverse small...

March 4, 2025

Boeing factory strike crosses 1-month mark as pressure...

October 16, 2024

Home prices hit record high in June on...

August 30, 2024

Amazon AI scammers duped investors out of millions...

March 20, 2025

JPMorgan Chase CEO Jamie Dimon on Trump tariffs: ‘Get...

January 23, 2025

Hurricane Milton could reduce Disney earnings, Goldman says

October 9, 2024

GM ditching ‘Ultium’ name for batteries and tech...

October 10, 2024

‘RFK’ing the french fries’: Steak ‘n Shake becomes...

March 18, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • S&P 500 Earnings for 2025 Q1 — Still Overvalued
    • Money’s Not Leaving the Market — It’s Rotating!
    • From Oversold to Opportunity: Small Caps on the Move
    • Tariffs and weaker beer demand are weighing on Modelo owner Constellation Brands
    • Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

      June 4, 2025

    Categories

    • Business (729)
    • Economy (975)
    • Politics (873)
    • Stocks (867)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.